Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TACE plus camrelizumab and apatinib versus TACE alone in unresectable hepatocellular carcinoma
CTR20220789Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started Aug 2022; status: active.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20220789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220789.